Christopher Fenimore - Regeneron Pharmaceuticals Vice President Controller

<div class='circular--portrait' style='background:#0D8ECF;color: white;font-size:4em;padding-top: 15px;;'>RE</div>
REGN -- USA Stock  

Earning Report: February 6, 2020  

Mr. Christopher Fenimore is Vice President, Controller of the Company. He was Vice President, Controller since March 2017. From January 2017 to March 2017, he served as Vice President, Deputy Controller, and previously served as Vice President, Financial Planning from January 2012 to December 2016. Prior to joining the Company in 2003, he was Vice President, Finance at Mojave Therapeutics, Inc. Mr. Fenimore prior experience includes working as a supervising senior accountant at KPMG, as well as healthcare industryfocused VC and investment banking roles. Mr. Fenimore holds an M.A. in Biotechnology from Columbia University, an M.B.A. in Professional Accounting from Rutgers Business School, and a B.A. in Economics from Rutgers University. Mr. Fenimore is a Certified Public Accountant in the State of New York.
Age: 47  President Since 2017  MBA    
914 847-7000
Fenimore holds an M.A. in Biotechnology from Columbia University, an M.B.A. in Professional Accounting from Rutgers Business School, and a B.A. in Economics from Rutgers University.

Christopher Fenimore Latest Insider Activity

Management Efficiency

The company has return on total asset (ROA) of 23.16 % which means that it generated profit of $23.16 on every $100 spent on asset. This is very large. Similarly, it shows return on stockholders equity (ROE) of 31.86 % meaning that it created $31.86 on every $100 dollars invested by stockholders.
The company currently holds 738 M in liabilities with Debt to Equity (D/E) ratio of 7.0 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Regeneron Pharmaceuticals has Current Ratio of 3.95 suggesting that it is liquid enough and is able to pay its financial obligations when they are due.

Similar Executives

Showing few of many executives


Samiran DasDr Reddys Laboratories Ltd
Kimberly WhiteVertex Pharmaceuticals Incorpor
Alejandro BernalZoetis
Heidi ChenZoetis
Douglas BoothePerrigo Company Plc
Marc CouckePerrigo Company Plc
Michael PariniVertex Pharmaceuticals Incorpor
James DillardPerrigo Company Plc
Charles WagnerVertex Pharmaceuticals Incorpor
Raghav ChariDr Reddys Laboratories Ltd
Umang VohraDr Reddys Laboratories Ltd
Ian SmithVertex Pharmaceuticals Incorpor
Charles MilsteinVertex Pharmaceuticals Incorpor
Jeffrey NeedhamPerrigo Company Plc
Clinton LewisZoetis
Catherine KnuppZoetis
K RaoDr Reddys Laboratories Ltd
J RamachandranDr Reddys Laboratories Ltd
Cartikeya ReddyDr Reddys Laboratories Ltd
Sripada ChandrasekharDr Reddys Laboratories Ltd
Roxanne LaganoZoetis

Entity Summary

Regeneron Pharmaceuticals, Inc., a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for treating various medical conditions worldwide. Regeneron Pharmaceuticals, Inc. was founded in 1988 and is headquartered in Tarrytown, New York. Regeneron Pharmaceuticals operates under Biotechnology classification in USA and is traded on BATS Exchange. It employs 7674 people.Regeneron Pharmaceuticals (REGN) is traded on BATS Exchange in USA and employs 7,674 people.

Regeneron Pharmaceuticals Leadership Team

Charles Baker, Independent Director
Joseph Goldstein, Independent Director
Anthony Coles, Independent Director
George Sing, Independent Director
Peter Powchik, Senior Vice President - Clinical Development
Jay Markowitz, Senior Vice President - Portfolio Management
Robert Terifay, Sr. VP of Commercial
Robert Landry, CFO and Sr. VP of Fin.
Michael Brown, Independent Director
Christine Poon, Independent Director
Neil Stahl, Executive VP of RandD
Marion McCourt, Senior Vice President and Head of Commercial
George Yancopoulos, Chief Scientific Officer and President - Regeneron Laboratories, Director
Huda Zoghbi, Director
Bonnie Bassler, Director
Joseph LaRosa, Senior Vice President General Counsel, Secretary
Daniel Plew, Senior Vice President General Manager - Industrial Operations and Product Supply
Leonard Schleifer, President CEO, Director
Alfred Gilman, Independent Director
Roy Vagelos, Chairman of the Board
Michael Aberman, Vice President - Strategy
Manisha Narasimhan, IR Contact
Douglas McCorkle, Vice President Controller, Assistant Treasurer
Marc TessierLavigne, Independent Director
Christopher Fenimore, Vice President Controller
Arthur Ryan, Independent Director

Stock Performance Indicators

Did you try this?

Run Headlines Timeline Now


Headlines Timeline

Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity
All  Next Launch Module

Currently Active Assets on Macroaxis

Purchased over 30 shares of
few hours ago
Traded for 80.1
Purchased over 300 shares of
few hours ago
Traded for 9.16
Purchased over 50 shares of
few hours ago
Traded for 58.39
Purchased over 70 shares of
few hours ago
Traded for 34.91
Purchased over 500 shares of
few hours ago
Traded for 5.02
Additionally take a look at Your Equity Center. Please also try Alpha Finder module to use alpha and beta coefficients to find investment opportunities after accounting for the risk.